Medpace (NASDAQ:MEDP) Reaches New 12-Month High on Strong Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $684.52 and last traded at $658.70, with a volume of 120,986 shares changing hands. The stock had previously closed at $662.48.

The company reported $4.84 EPS for the quarter, topping the consensus estimate of $4.44 by $0.40. The business had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the business posted $3.86 earnings per share.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Quarterly results exceeded expectations. Medpace earned $4.84 per share, above the $4.44–$4.45 analyst consensus and up from $3.86 a year earlier. Revenue increased 8.5% year over year to $716 million, narrowly exceeding the $714.47 million estimate. Medpace Holdings Profit Climbs in Q3
• Positive Sentiment: Margin expansion supported the earnings beat. Coverage highlighted improved profitability as a key driver of the 8.5% EPS beat, reinforcing Medpace’s earnings-growth story. The company reported a 17.67% net margin and 110.15% return on equity. Medpace Q3 2026 Earnings
• Positive Sentiment: Management provided an above-consensus 2026 earnings outlook. The guidance was described as higher than Wall Street expectations, which could support analyst estimate revisions and investor confidence. Medpace 2026 Earnings Guidance
• Positive Sentiment: The board authorized a $1 billion share repurchase. The buyback provides a significant capital-return commitment and may support per-share earnings over time, although the pace of repurchases remains uncertain. Medpace Gets $1 Billion Buyback Authorization
• Negative Sentiment: The initial market reaction was cautious. MEDP slipped despite the earnings beat and favorable outlook, suggesting investors may have viewed the report as broadly in line or remain concerned that revenue growth was not strong enough to justify the stock’s elevated valuation. Medpace Slips Despite Third-Quarter Beat

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent analyst reports. Mizuho lifted their price objective on shares of Medpace from $665.00 to $700.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings raised Medpace from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $607.73.

Insider Buying and Selling

In other Medpace news, CEO August Troendle sold 21,966 shares of Medpace stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares in the company, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 336,140 shares of company stock valued at $208,008,328. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Medpace

Several hedge funds have recently made changes to their positions in MEDP. Root Financial Partners LLC purchased a new stake in Medpace in the 3rd quarter valued at approximately $198,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Medpace during the 3rd quarter worth approximately $1,791,000. Crossmark Global Holdings Inc. raised its stake in shares of Medpace by 3.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 6,312 shares of the company’s stock worth $3,940,000 after buying an additional 218 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Medpace by 14.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,044 shares of the company’s stock worth $652,000 after buying an additional 131 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its stake in shares of Medpace by 6.9% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,360 shares of the company’s stock worth $3,369,000 after buying an additional 344 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 0.6%

The business has a 50 day moving average price of $608.40 and a 200-day moving average price of $535.64. The firm has a market capitalization of $18.37 billion, a PE ratio of 38.61, a P/E/G ratio of 2.78 and a beta of 1.18.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.